Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer

NCT00112905 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00112905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2005
Completion date
March 31, 2008
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the bladder, distal urethral cancer, metastatic transitional cell cancer of the renal pelvis and ureter, proximal urethral cancer, recurrent bladder cancer, recurrent transitional cell cancer of the renal pelvis and ureter, recurrent urethral cancer, regional transitional cell cancer of the renal pelvis and ureter, squamous cell carcinoma of the bladder, stage iii bladder cancer, stage iv bladder cancer, transitional cell carcinoma of the bladder, urethral cancer associated with invasive bladder cancer